NewsRoom Articles - Page 4 of 225

FridayDec 19, 2025 9:00 am

US House Passes Republican Healthcare Bill, ACA Extension Left Out

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of the ACA tax credits that were at the heart of the recent government shutdown. This bill now heads to the Senate for consideration. On Wednesday, the exclusion of a provision extending the ACA tax credits triggered a revolt within the GOP ranks as some moderates in their ranks joined Democrats in signing a discharge petition that would compel the House to conduct a vote on extending the tax credits for 3 years. However, none of the Republicans who signed this petition eventually voted against the…

ThursdayDec 18, 2025 10:00 am

Chronic Inflammation Could Be the Missing Key to Understanding Long Covid

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human Services. For a long time, the scientific community has struggled to find out why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid. Now a new study has established that the key driver among people with long Covid could be chronic inflammation and this opens new pathways to treating the condition. The study, conducted by a team at Beth Israel Medical Center and Harvard University analyzed blood samples taken from 140 individuals who never suffered from Covid, those who got infected…

WednesdayDec 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its Deciparticle platform Oncotelic is leveraging the very concepts of nanoparticle-mediated delivery in a real-world clinical context In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.…

TuesdayDec 16, 2025 10:00 am

Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment

A new study done in India has produced results that bring into question the longstanding assumption that treating cancer requires tumors to be destroyed. The researchers attained remarkable results by using another approach, treating the tumor rather than attacking it, and their approach was effective in taming the aggressiveness of glioblastoma while also toning down many biomarkers that indicate the severity of the cancer. For a while, many researchers have been growing in conviction that the way cancer is treated needs to change from efforts geared at destroying cancer cells (through chemotherapy, surgery and radiation) to regarding cancer as a wound that needs to be helped to heal. This thinking was first…

MondayDec 15, 2025 9:45 am

Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics

Industry data shows small molecules achieve 5–10% approval rates over 15–20 years; antisense oligonucleotides (“ASOs”) are shifting the odds through rational design. Six new antisense drugs gained FDA approval in 2023–2024, bringing total approvals above 20; evidence of accelerating regulatory momentum. Oncotelic Therapeutics’ OT-101 (Trabedersen) is the only TGF-β2-specific antisense in Phase 3 trials, targeting pancreatic cancer and other resistant malignancies. The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates…

FridayDec 12, 2025 10:00 am

Study Highlights Increasing Cases of Breast Cancer in Younger Women

A study that involved an analysis of patient records in New York has discovered that breast cancer, and especially aggressive forms of this cancer, is occurring at a higher rate among younger women aged below 40. This group is currently regarded as low risk for breast cancer by the existing screening guidelines, and this calls for a review of those guidelines. The study analyzed data spanning 11 years taken from 2014 to the end of 2024. These outpatient records were taken from seven medical facilities that covered an area of approximately 200 miles in Western New York State. The team…

ThursdayDec 11, 2025 10:00 am

Health Experts Suggest How Public Trust Can Be Restored in US Healthcare

After the pandemic, public trust in the U.S. healthcare system plummeted, and officials at the local level took the hardest hit when compared to federal health officials. As things stand, even state and federal health officials are losing even the little trust that the public still had in them. For a healthcare system to function, public trust is vital because people want to believe that the professionals they entrust with their health have their best interests at heart. It is therefore alarming that public trust in healthcare professionals is at an all-time low, and fixing the healthcare crisis needs to…

TuesdayDec 09, 2025 10:00 am

US to End Mandatory Vaccination of Newborns Against Hepatitis B

Since 1991, there has existed a recommendation requiring all newborns to receive a vaccine against Hepatitis B at birth. However, an advisory panel on vaccines voted on Friday to end this recommendation and instead recommended that only babies whose mothers have had a positive test for hepatitis B should receive the shot at birth. The panel in question, ACIP (Advisory Committee on Immunization Practices), advises the CDC on vaccination policy in the U.S. During their recent meeting, the panel voted 8-3 in favor of letting individuals decide whether to have their newborns receive the vaccine or not. This only applies…

MondayDec 08, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone

The report maintains $25 per share valuation for Soligenix, based on a probability-adjusted discounted cash flow model that considers potential future revenues. The centerpiece of the Zacks analysis focuses on what is characterized as a “very encouraging” 48% blinded response rate. With 50 patients now enrolled out of a planned 80-patient study, the company remains on track for the interim analysis to occur in the second quarter of 2026. When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something significant.…

FridayDec 05, 2025 10:00 am

Nasal Drops Hold Promise in Fighting Deadly Brain Cancer

The fight against glioblastoma, a deadly brain cancer, has been boosted by new research conducted at Washington University that has developed nasal drops which can travel through nerves found in the nose and reach different parts of our central nervous system in order to fight the glioblastoma cells there. Preliminary results revealed that this novel medication safely reached the intended target and protected the mice against the fatal tumors. Alexander Stegh, a neurosurgeon at the university, explains that their approach offers hope for more effective and safer treatments for this deadliest brain cancer and possibly other cancers that are resistant…